Stattic

For research use only. Not for use in humans.

目录号：S7024

CAS No. 19983-44-9

Stattic 是第一个非肽类STAT3小分子抑制剂，有效抑制STAT3激活和核易位，IC50为5.1 μM，其作用于STAT3的选择性远高于STAT1。Stattic 可诱导凋亡。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 730.64	现货
25mg	RMB 901.23	现货
50mg	RMB 1392.12	现货
100mg	RMB 2375.1	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Stattic发表文献139篇：

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cell Metab, 2020, 31(2):327-338

PubMed: 31928884 ( click the link to review the publication )

Nat Med, 2018, 24(5):563-571

PubMed: 29713085 ( click the link to review the publication )

Cell, 2017, 7;170(6):1134-1148.e10.

PubMed: 28886382 ( click the link to review the publication )

Oncogenesis, 2021, 10(1):8

PubMed: 33431808 ( click the link to review the publication )

Ecotoxicol Environ Saf, 2021, 208:111693

PubMed: 33396024 ( click the link to review the publication )

Cell Rep, 2020, 30(3):793-806

PubMed: 31968254 ( click the link to review the publication )

Elife, 2020, 30;9. pii: e51317

PubMed: 32223889 ( click the link to review the publication )

J Hematol Oncol, 2020, 5;13(1):68

PubMed: 32503584 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32045997 ( click the link to review the publication )

Cancers (Basel), 2020, 12(3)

PubMed: 32150944 ( click the link to review the publication )

Cell Death Discov, 2020, 2;6:42

PubMed: 32528731 ( click the link to review the publication )

J Mol Cell Biol, 2020, 1 pii: mjaa011

PubMed: 32236560 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):505

PubMed: 33246502 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 2020:6584059

PubMed: 33274004 ( click the link to review the publication )

Oxid Med Cell Longev, 2020,

PubMed: 32855767 ( click the link to review the publication )

J Am Heart Assoc, 2020, 9(18):e017071

PubMed: 32865099 ( click the link to review the publication )

Front Oncol, 2020, 5;10:652

PubMed: 32432040 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.15563

PubMed: 32618105 ( click the link to review the publication )

Biochem Pharmacol, 2020, S0006-2952(20)30632-8

PubMed: 33359364 ( click the link to review the publication )

Cancer Immunol Immunother, 2020, 69(1):115-126

PubMed: 31802182 ( click the link to review the publication )

Int J Mol Sci, 2020,

PubMed: 32823915 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(3)

PubMed: 32046095 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:405

PubMed: 32863764 ( click the link to review the publication )
Cell Mol Neurobiol, 2020, 18

PubMed: 32424774 ( click the link to review the publication )

Invest New Drugs, 2020, 20

PubMed: 32436058 ( click the link to review the publication )

Life Sci, 2020, 242:117221

PubMed: 31881224 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

PLoS One, 2020, 15(11):e0242337

PubMed: 33180876 ( click the link to review the publication )

Int J Oral Sci, 2020, 12(1):38

PubMed: 33380723 ( click the link to review the publication )

Hum Exp Toxicol, 2020, 39(2):224-234

PubMed: 31610697 ( click the link to review the publication )

Exp Clin Endocrinol Diabetes, 2020, 10.1055/a-0998-7985

PubMed: 31896157 ( click the link to review the publication )

Pharmacol Res, 2020, 153:104661

PubMed: 31982491 ( click the link to review the publication )

J Cell Physiol, 2020, 235(2):1076-1089

PubMed: 31276203 ( click the link to review the publication )

Cell Signal, 2020, 65:109413

PubMed: 31494257 ( click the link to review the publication )

FASEB Bioadv, 2020, 2(2):116-125

PubMed: 32123861 ( click the link to review the publication )

Front Immunol, 2020, 11:2031

PubMed: 33042115 ( click the link to review the publication )

J Invest Dermatol, 2020, S0022-202X(20)31981-3

PubMed: 32805217 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2020, S2352-345X(20)30190-9

PubMed: 33238220 ( click the link to review the publication )

Oncotarget, 2020, 11(33):3129-3143

PubMed: 32913557 ( click the link to review the publication )

Int Immunopharmacol, 2020, 81:106143

PubMed: 32062080 ( click the link to review the publication )

Cell Death Dis, 2020, 11(7):531

PubMed: 32661236 ( click the link to review the publication )

Nat Commun, 2019, 10(1):716

PubMed: 30755611 ( click the link to review the publication )

Biomaterials, 2019, 219:119371

PubMed: 31352310 ( click the link to review the publication )

Mol Cancer, 2019, 18(1):40

PubMed: 30866952 ( click the link to review the publication )

Diabetes, 2019, 68(6):1303-1314

PubMed: 30936144 ( click the link to review the publication )

Redox Biol, 2019, 24:101189

PubMed: 30986607 ( click the link to review the publication )

Redox Biol, 2019, 20:451-457

PubMed: 30439686 ( click the link to review the publication )
Brain Behav Immun, 2019, 81:228-246

PubMed: 31207335 ( click the link to review the publication )

J Pathol, 2019, 248(4):438-451

PubMed: 30900255 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):322

PubMed: 31331377 ( click the link to review the publication )

EBioMedicine, 2019, 39:132-144

PubMed: 30528455 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)E1939

PubMed: 31817171 ( click the link to review the publication )

Ther Adv Med Oncol, 2019, 11:1758835919846806

PubMed: 31205504 ( click the link to review the publication )

Cell Biol Toxicol, 2019, 10.1007/s10565-019-09471-x

PubMed: 30941654 ( click the link to review the publication )

Kidney Blood Press Res, 2019, 44(6):1453-1464

PubMed: 31722339 ( click the link to review the publication )

Oncogenesis, 2019, 8(8):39

PubMed: 31311917 ( click the link to review the publication )

Front Oncol, 2019,

PubMed: 31019895 ( click the link to review the publication )

J Virol, 2019, 93(9)

PubMed: 30787154 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31575039 ( click the link to review the publication )

J Clin Periodontol, 2019, 10.1111/jcpe.13166

PubMed: 31286538 ( click the link to review the publication )

Respir Res, 2019, 20(1):184

PubMed: 31416461 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:1309-1319

PubMed: 30804683 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 380:114698

PubMed: 31394157 ( click the link to review the publication )

Cytokine, 2019, 119:81-89

PubMed: 30903867 ( click the link to review the publication )

J Cell Biochem, 2019, 120(4):5315-5325

PubMed: 30320916 ( click the link to review the publication )

Int J Oncol, 2019, 10.3892/ijo.2019.4880

PubMed: 31545422 ( click the link to review the publication )

Cancer Med, 2019, 8(17):7345-7358

PubMed: 31631559 ( click the link to review the publication )

Mol Immunol, 2019, 111:162-171

PubMed: 31063937 ( click the link to review the publication )

Oncol Rep, 2019, 41(1):437-446

PubMed: 30365081 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:1137-1146

PubMed: 30809095 ( click the link to review the publication )

Scand J Immunol, 2019, 89(6):e12761

PubMed: 30977163 ( click the link to review the publication )
Evid Based Complement Alternat Med, 2019, 2019:3909468

PubMed: 31485245 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3803-3808

PubMed: 31262907 ( click the link to review the publication )

Pathol Res Pract, 2019, 215(6):152392

PubMed: 30922625 ( click the link to review the publication )

Am J Nucl Med Mol Imaging, 2019,

PubMed: 31976162 ( click the link to review the publication )

Immunity, 2018, 48(4):787-798

PubMed: 29653697 ( click the link to review the publication )

Circulation, 2018, 30;138(18):2021-2035

PubMed: 29967195 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1523

PubMed: 29670076 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(24):6236-6247

PubMed: 30131384 ( click the link to review the publication )

Blood Cancer J, 2018, 8(2):20

PubMed: 29440639 ( click the link to review the publication )

Cancer Lett, 2018, 436:52-62

PubMed: 30118844 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):375

PubMed: 29515107 ( click the link to review the publication )

Front Immunol, 2018,

PubMed: 29867938 ( click the link to review the publication )

Mol Oncol, 2018, 12(7):1203-1215

PubMed: 29791786 ( click the link to review the publication )

Carcinogenesis, 2018, 39(9):1165-1175

PubMed: 29893810 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(3):489-501

PubMed: 29637003 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(11):1057-1064

PubMed: 30277836 ( click the link to review the publication )

Cell Cycle, 2018, 17(4):428-438

PubMed: 29468929 ( click the link to review the publication )

Int Immunopharmacol, 2018, 58:136-144

PubMed: 29587202 ( click the link to review the publication )

Transl Oncol, 2018, 11(2):487-497

PubMed: 29494948 ( click the link to review the publication )

Int J Mol Med, 2018, 42(1):497-504

PubMed: 29620257 ( click the link to review the publication )

Eur Rev Med Pharmacol Sci, 2018, 22(19):6308-6314

PubMed: 30338828 ( click the link to review the publication )

Scand J Immunol, 2018, 88(3):e12703

PubMed: 30047999 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(4):370-380

PubMed: 29471502 ( click the link to review the publication )

Tumour Biol, 2018, 40(1):1010428317731369

PubMed: 29320977 ( click the link to review the publication )
Circ Res, 2017, 121(6):617-627

PubMed: 28743805 ( click the link to review the publication )

Cell Death Dis, 2017, 8(4):e2725

PubMed: 28383559 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2234-2245

PubMed: 28729401 ( click the link to review the publication )

J Mol Med (Berl), 2017, 95(2):221-233

PubMed: 27709266 ( click the link to review the publication )

Am J Cancer Res, 2017, 7(3):433-447

PubMed: 28401002 ( click the link to review the publication )

Biochem Pharmacol, 2017, 136:40-50

PubMed: 28404378 ( click the link to review the publication )

Sci Rep, 2017, 7(1):11540

PubMed: 28912535 ( click the link to review the publication )

Am J Pathol, 2017, 187(5):980-986

PubMed: 28284718 ( click the link to review the publication )

Cell Signal, 2017, 32:48-58

PubMed: 28093267 ( click the link to review the publication )

PLoS One, 2017, 12(6):e0178844

PubMed: 28636670 ( click the link to review the publication )

Gene, 2017, 627:114-122

PubMed: 28603075 ( click the link to review the publication )

Mol Med Rep, 2017, 16(6):9111-9119

PubMed: 28990062 ( click the link to review the publication )

Int J Clin Exp Pathol, 2017, 10(7):7466-7474

PubMed: 31966590 ( click the link to review the publication )

Oncotarget, 2017, 8(8):13174-13185

PubMed: 28061458 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29100353 ( click the link to review the publication )

Sci Rep, 2017, 10.1038/srep41404

PubMed: 28112250 ( click the link to review the publication )

Oncotarget, 2017, 8(37):61876-61889

PubMed: 28977911 ( click the link to review the publication )

Oncotarget, 2017, 8(19):31227-31237

PubMed: 28415722 ( click the link to review the publication )

Leukemia, 2016, 30(6):1311-9

PubMed: 26854024 ( click the link to review the publication )

Cell Rep, 2016, 15(3):460-470

PubMed: 27068459 ( click the link to review the publication )

EBioMedicine, 2016, 8:132-149

PubMed: 27428425 ( click the link to review the publication )

Cell Death Dis, 2016, 7:e2294

PubMed: 27415424 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1863(7 Pt A):1579-88

PubMed: 27066979 ( click the link to review the publication )

Int J Cardiol, 2016, 210:85-92

PubMed: 26930642 ( click the link to review the publication )
Cancer Prev Res (Phila), 2016, 9(8):657-63

PubMed: 27267892 ( click the link to review the publication )

Mol Carcinog, 2016, 55(12):2010-2023

PubMed: 26663388 ( click the link to review the publication )

Int J Oncol, 2016, 48(1):161-72

PubMed: 26549725 ( click the link to review the publication )

J Physiol Sci, 2016, 66(3):229-39

PubMed: 26541157 ( click the link to review the publication )

Inflamm Res, 2016, 65(3):193-202

PubMed: 26621504 ( click the link to review the publication )

Antioxid Redox Signal, 2015, 24(2):70-83

PubMed: 26154696 ( click the link to review the publication )

Neoplasia, 2015, 17(7):586-97

PubMed: 26297436 ( click the link to review the publication )

Transl Res, 2015, 166(4):384-98

PubMed: 25843671 ( click the link to review the publication )

Hum Pathol, 2015, 46(2):284-94

PubMed: 25537973 ( click the link to review the publication )

FEBS Lett, 2015, 589(1):52-8

PubMed: 25436422 ( click the link to review the publication )

FEBS Lett, 2015, 589(1):52-8

PubMed: ( click the link to review the publication )

PLoS One, 2015, 10(5):e0128406

PubMed: 26010889 ( click the link to review the publication )

J Interferon Cytokine Res, 2015, 10.1089/jir.2014.0128

PubMed: 25919795 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43992-4004

PubMed: 26556857 ( click the link to review the publication )

Tumour Biol, 2015, 10.1007/s13277-015-3681-y

PubMed: 26124007 ( click the link to review the publication )

Oncotarget, 2015, 6(10):8244-54

PubMed: 25749519 ( click the link to review the publication )

J Exp Med, 2015, 212(12):2147-63

PubMed: 26552708 ( click the link to review the publication )

Tumour Biol, 2015, 36(12):9475-86

PubMed: 26124007 ( click the link to review the publication )

J Biol Chem, 2013, 288(8):5553-61

PubMed: 23303179 ( click the link to review the publication )

产品安全说明书

STAT抑制剂选择性比较

生物活性

产品描述

Stattic 是第一个非肽类STAT3小分子抑制剂，有效抑制STAT3激活和核易位，IC50为5.1 μM，其作用于STAT3的选择性远高于STAT1。Stattic 可诱导凋亡。

特性

Stattic是第一个非肽类小分子，抑制STAT3 SH2结构域的功能，无论在体外STAT3磷酸化状态。

靶点

STAT3 ^[1]
(Cell-free assay)

5.1 μM

体外研究

Stattic抑制gp130受体衍生的含磷酸化酪氨酸的肽结合到STAT3 SH2结构域，这种作用存在强烈的温度依赖性。Stattic对酪氨酸磷酸化的肽结合到酪氨酸激酶Lck的SH2结构域只有很微弱的作用效果。Stattic不抑制其他两个二聚体转录因子(c-Myc/Max 和 Jun/Jun)的二聚化。Stattic抑制荧光素标记的磷酸化肽段结合到STAT1和STAT5b的SH2域。Stattic浓度为10 μM，选择性抑制DNA与STAT3二聚体结合。Stattic抑制STAT3在Tyr705位点磷酸化，而对STAT1在Tyr701(HepG2细胞)位点磷酸化或 JAK1, JAK2, 和c-Src(MDA-MB-231和MDA-MB-235S细胞)磷酸化几乎没有抑制效果。Stattic增加STAT3依赖性的乳腺癌细胞系的凋亡率。^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
H9c2	NXK5PJZFTnWwY4Tpc44hSXO\|YYm=	NYDYOVltOTEkgJpOwG0>	NIDZS2U16oDLaB?=		MlTBdoV3\XK\|ZYOgeIhmKGWoZnXjeJMhd2ZiSVytNlc>	NF;q[2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkOzPVY{Oyd-Mk[zN\|k3OzN:L3G+
NPC	M{LTXmZ2dmO2aX;uJGF{e2G7	NHjk[msxNTdwNTFCuW0>			MXvhZo9tcXOqZYOgSW1VNWyra3WgcY9t\WO3bHHyJIFtfGW{YYTpc45{NCCjbnSgZ4VtdCCvaXfyZZRqd25iYX7kJIlvfmG\|aX;uJIlv\HWlZXSgZpkhWkuLUDDrco9kc2Sxd36=	MkL3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MUW0N\|AoRjJ3OUG1OFMxRC:jPh?=
HASMC	Mom1SpVv[3Srb36gRZN{[Xl?	NIDpPZUyNjJ3LUWg{txO	M1nKVlIxKG2rbh?=	M{[5SWROW00EoB?=	NV;4R416cW6qaXLpeJMheC1qWTmtV3RCXC1zLEOsOUB{cWewYXzzxsA>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh2OU[yNkc,OjV6NEm2NlI9N2F-
H9c2	MXvGeY5kfGmxbjDBd5NigQ>?	NHXENG4zNzFyIN88US=>	Mn7aNkBp	MWHEUXNQyqB?	NV[3b5JM[WK{b3fheIV{yqC2aHWgZ5l1d3C{b4TlZ5RqfmViZX\m[YN1eyCxZjDJUE0zPyCjZ3HpcpN1KFOK	M2SwcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEKwPVA4Lz5{NUiyNFkxPzxxYU6=
A431	NYjHWZk1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljiNuKh\|ryP	MX2yxsBp		NVW3VG1Z[myxY3vzJGVITi2{ZY\ldpNm\CCmZXPy[YF{\XNiaX6gZ4VtdCC4aXHibYxqfHl?	NV\qUGFVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NlA1OzVpPkK1O\|IxPDN3PD;hQi=>
A431	M1u4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mkj3NuKh\|ryP	Mm\4NuKhcA>?		NUHTS3R6cW6lcnXhd4V{KGmwIHHwc5B1d3OrczDpcoR2[2WmIHL5JJNpcWuxbnnu	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{MESzOUc,OjV5MkC0N\|U9N2F-
SiHa	MXvD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NFrqNng2NTd3IH7N	MWSyOOKhcMLi		NHq3SJh{cG:5czDtc5JxcG:ub3f5JI9nKGFidInwbYNidCCjcH;weI91cWNiY3XscEBidmRiZH;z[U1l\XCnbnTlcpQhdG:\|czDv[kBk\WyuII\pZYJqdGm2edMg	MnHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3M{m2OFQoRjJ3NUO5OlQ1RC:jPh?=
SiHa	NYTXXJcyTnWwY4Tpc44hSXO\|YYm=	M1jCTlUuPzVibl2=	NXzx[mZQOjUEoHlCpC=>		MlXpdoVlfWOnczD0bIXDqHCqb4PwbI9zgWyjdHnvckBifCC2aHWgeJlzd3OrbnWgdoV{cWS3ZTC3NFXDqA>?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV\|OU[0OEc,OjV3M{m2OFQ9N2F-
ECA109	MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY[5WndsOC1{MDFOwG0>	Ml7hNlTDqGkEoB?=		NX7wTnY4UUN3ME21MlUxKM7:TR?=	MnnyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2OUK0PFAoRjJ3NEmyOFgxRC:jPh?=
TE13	NFHCR2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\jNE0zOCEQvF2=	Mn22NlTDqGkEoB?=		NH:5[4dKSzVyPU[uNVXDqM7:TR?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR7MkS4NEc,OjV2OUK0PFA9N2F-
KYSE150	Moi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXSwMVIxKM7:TR?=	MnPGNlTDqGkEoB?=		M4L0W2lEPTB;MUKuOlTDqM7:TR?=	NVjFTHp5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0PVI1QDBpPkK1OFkzPDhyPD;hQi=>
ECA109	MX3DcI9vd2enbnnjJHN2en[rdnHsJGF{e2G7	NH23bmgxNjYEoN88US=>	MViyOOKhcMLi		NVe2TGNZe3WycILld5NmeyC2aHWgZ4xwdm:pZX7pZ{Bnd3KvYYTpc44>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR7MkS4NEc,OjV2OUK0PFA9N2F-
TE13	M{O4ZmNtd26xZ3XubYMhW3W{dnn2ZYwhSXO\|YYm=	MlPsNE42yqEQvF2=	NWOw[4ZpOjUEoHlCpC=>		NHrqTm9{fXCycnXzd4V{KHSqZTDjcI9vd2enbnnjJIZwem2jdHnvci=>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR7MkS4NEc,OjV2OUK0PFA9N2F-
KYSE150	NGLEemJEdG:wb3flcolkKFO3co\peoFtKEG\|c3H5	M3zSZVAvPcLizszN	M3XKZlI1yqCqwrC=		MWDzeZBxemW\|c3XzJJRp\SClbH;uc4dmdmmlIH\vdo1ifGmxbh?=	NX\uXnlpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0PVI1QDBpPkK1OFkzPDhyPD;hQi=>
ECA109	M33R[WZ2dmO2aX;uJGF{e2G7	NFnib3MxNjYEoN88US=>	Mm\YNlTDqGkEoB?=		Mk\m[Y5p[W6lZYOgTXIucW6mdXPl[EBo\W6ncnH0bY9vKG:oIFTTRpM>	NHnQW4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS5NlQ5OCd-MkW0PVI1QDB:L3G+
PC3M-1E8	MV3GeY5kfGmxbjDBd5NigQ>?	NYr5fHRIOi53L{WvNVAh\|ryP	NUfOXlVqOC12IHi=		Mnu1bY5pcWKrdIOgeIhmKFOWQWSzJIFkfGm4YYTpc44hcW5iYTDkc5NmNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVzyqB?	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4MUO2OUc,OjV{NkGzOlU9N2F-
PC3M-1E8	MWrGeY5kfGmxbjDBd5NigQ>?	MXWxNEDPxE1?	NUfIdm9rOjRiaB?=		Mm\m[I94dnKnZ4XsZZRmeyCEY3ytfGwtKHO3co\peolvKGGwZDDjMW16[w>?	M3XLcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[xN\|Y2Lz5{NUK2NVM3PTxxYU6=
PC3M-1E8	MYTGeY5kfGmxbjDBd5NigQ>?	NYizNnJxOTBizszN	MlO0NlQhcA>?		M3PxWIlvcGmkaYTzJGlNNTZiaX7keYNm\CCVVFHUN{Bi[3SrdnH0bY9vKGGwZDD0bIUhUUxvNj3pcoR2[2WmIGPURXQ{KGGldHn2ZZRqd25?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4MUO2OUc,OjV{NkGzOlU9N2F-
PC3M-1E8	M2Djb2Ntd26xZ3XubYMhW3W{dnn2ZYwhSXO\|YYm=	MkPpNk42NzVxMUCg{txO			MXvpcohq[mm2c9MgeIhmKGOxbH;ufUBnd3KvYYTpc44he2mpbnnmbYNidnSueR?=	NV\pRW9[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlE{PjVpPkK1NlYyOzZ3PD;hQi=>
MDA-MB-231	NV7RPIZ{TnWwY4Tpc44hSXO\|YYm=	MljWNlAh\|ryP	NYDIUmdXOiCq		M{SzPYV5cGmkaYTzJHNv[WmuIHHu[EBGNWOjZHjldolvKGW6cILld5Nqd25?	NHrB[mg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG1N\|M1QSd-MkWxOVM{PDl:L3G+
H9c2	NXrtbXBoTnWwY4Tpc44hSXO\|YYm=	MoS1NlAhyrWP	MW[zNEBucW5?	NHjvSYhFVVORwrC=	MYDhZo9tcXOqZYOgdJJweG:ob3ytbY5lfWOnZDDBT3QheGixc4Doc5J6dGG2aX;uJIF1KGKxdHigd4VzPDd\|IHHu[EB1cHJ\|MEi=	MkDuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMEWwOlcoRjJ3MUC1NFY4RC:jPh?=
HaCaT	NX:0TmRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTBbG9DOTBiwsXN	NF\HZ\|MzOCCvaX6=	M1fFemROW00EoB?=	NVzD[3E4\W6qYX7j[ZMhe2:{YX\lcoljNSCjbnSgd5VvcXSrbnniMYlv\HWlZXSg[5Jwf3SqIHnubIljcXSrb36=	Mkj1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMUO5NFcoRjJ3MEGzPVA4RC:jPh?=
Caki-1	NHuyR5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLyNVAhyrWP	NVnafWplOjBibXnu	M{\jOmROW00EoB?=	Mlrk[Y5p[W6lZYOgd49z[W[nbnniMUBidmRic4XubZRqdmmkLXnu[JVk\WRiZ4Lve5RpKGmwaHnibZRqd25?	M3XKd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEGzPVA4Lz5{NUCxN\|kxPzxxYU6=
HaCaT	MVPBdI9xfG:\|aYOgRZN{[Xl?	NX:1WXJVOTBiwsXN	NW\odHJVOjBibXnu	M{PxWmROW00EoB?=	M3racIlv[3KnYYPld{Bxem:yb4L0bY9veyCxZjDhdI9xfG:2aXOgZ4VtdHNiZIXlJJRwKHS{ZXH0cYVvfCC5aYToJJNwemGoZX7pZkBweiC\|dX7peIlvcWJ?	MoK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMUO5NFcoRjJ3MEGzPVA4RC:jPh?=
FHL-primed hNSCs	MXXD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MmLiNE4xOi13IN88US=>	Ml\uO\|IhcA>?		NXTXUI5mdGWjZIOgeI8hfGinIHzvd5Mhd2ZiY3XscEB3cWGkaXzpeJkh[XRiaHnnbEBkd26lZX70doF1cW:w	NYLIOXM1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFU1OzRpPkK0PVQ2PDN2PD;hQi=>
ELL-primed hNSCs	NVv5RWgzS2WubDDWbYFjcWyrdImgRZN{[Xl?	Mo\wNE4xOi13IN88US=>	M3niW\|czKGh?		NIHZR4Vt\WGmczD0c{B1cGVibH;zd{Bw\iClZXzsJJZq[WKrbHn0fUBifCCqaXfoJINwdmOnboTyZZRqd25?	M{LGOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS1OFM1Lz5{NEm0OVQ{PDxxYU6=
SS	NEXWXIFE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NEPZ[WIyNTFyIN88US=>	NXnDe\|l4PzJiaB?=	M2rBSmROW09?	MXrjZZV{\XNiYTDkc5NmNWSncHXu[IVvfCCrbnjpZol1cW:wIH;mJJRp\SC4aXHibYxqfHoEoB?=	M3zTUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{W2NVEyLz5{NEe1OlEyOTxxYU6=
SeAx	M2fjemNmdGxiVnnhZoltcXS7IFHzd4F6	MUmxMVExKM7:TR?=	NEH0eIQ4OiCq	MUjEUXNQ	NEXxZmpk[XW\|ZYOgZUBld3OnLXTldIVv\GWwdDDpcohq[mm2aX;uJI9nKHSqZTD2bYFjcWyrdIpCpC=>	MoDVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NU[xNVEoRjJ2N{W2NVEyRC:jPh?=
HuT-78	MmKyR4VtdCCYaXHibYxqfHliQYPzZZk>	M{XFdVEuOTBizszN	NILkZZc4OiCq	MVrEUXNQ	MWDjZZV{\XNiYTDkc5NmNWSncHXu[IVvfCCrbnjpZol1cW:wIH;mJJRp\SC4aXHibYxqfHoEoB?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd3NkGxNUc,OjR5NU[xNVE9N2F-
CD4+	NIHa[4dCeG:ydH;zbZMhSXO\|YYm=	NWLmS4c6OTEkgJpOwI0>	MnvmNlQhcA>?	M3W5WGROW09?	MWTpcoR2[2W\|IHHwc5B1d3OrczDzeJJwdmeueR?=	NIrNNIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe1OlEyOSd-MkS3OVYyOTF:L3G+
MCF-7	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjV[Y4xNjR4OT2zMlc2KM7:TR?=	NYm2SoQ6PSCm		MorWdoVlfWOnczDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{OEC3PEc,OjR5MkiwO\|g9N2F-
MCF-7/LCC1	NIPLWoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXiwXVZrOC52NkmtN{44PSEQvF2=	MV61JIQ>		MX\y[YR2[2W\|IHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl?	NFruRZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyPFA4QCd-MkS3NlgxPzh:L3G+
MCF-7/LCC9	Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;Te\|AvPDZ7LUOuO\|Uh\|ryP	MorGOUBl		MmDwdoVlfWOnczDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7	NX7XVo5rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3NlgxPzhpPkK0O\|I5ODd6PD;hQi=>
HaCaT	NX\aT2JxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3lNVAhyrWP	MUeyNEBucW5?	MX3EUXNQyqB?	MVflcohidmOnczDleoVzd2yrbYXzMYlv\HWlZXSgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdg>?	M3HjTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzNVMyLz5{NESyN\|E{OTxxYU6=
HaCaT	M2nWXGFxd3C2b4Ppd{BCe3OjeR?=	NF3sbmcyOCEEtV2=	NGTDVHUzOCCvaX6=	NGfyO3pFVVORwrC=	NH25TYlmdmijbnPld{B1cGViYYDvdJRwfGmlIHXm[oVkfHNib3[g[ZZmem:uaX31dy=>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{GzNUc,OjR2MkOxN\|E9N2F-
MDA-MB-231	MWrGeY5kfGmxbjDBd5NigQ>?	NHrqdGUyOCEEtV2=	NVvwb5BGOjRiaB?=	M{DPRmROW00EoB?=	Mn;idoVlfWOnczDQMXNVSVR\|IHX4dJJme3Orb36=	M3zRdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{e2OVg3Lz5{NEO3OlU5PjxxYU6=
SUM-159	NUHnOpZ6TnWwY4Tpc44hSXO\|YYm=	MVGxNEDDvU1?	NWDydHNYOjRiaB?=	NUjOfmN7TE2VT9Mg	MV\y[YR2[2W\|IGCtV3RCXDNiZYjwdoV{e2mxbh?=	NFrVS4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO3OlU5Pid-MkSzO\|Y2QDZ:L3G+
SK-BR-3	M{DW[WZ2dmO2aX;uJGF{e2G7	MWqxNEDDvU1?	M3mwOFI1KGh?	M4fNUGROW00EoB?=	NIjLRYtz\WS3Y3XzJHAuW1SDVEOg[ZhxemW\|c3nvci=>	MkXkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|N{[1PFYoRjJ2M{e2OVg3RC:jPh?=
MCF7-HER2	MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLLNE0yOCEQvF2=	NVjje3FrPDhiaB?=	NVi5eZpSTE2VTx?=	NIHlW3BqdmS3Y3XzJINmdGxiZHXheIgh\G:\|ZTDk[ZBmdmSnboTsfS=>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7N{WwPEc,OjR{OUe1NFg9N2F-
MCF7-HER2	NYLCXWl[TnWwY4Tpc44hSXO\|YYm=	NHuzcZQ2KM7:TR?=	NEjVTWYzPCCq	NInsOphFVVOR	NF7yc4hlcW2rbnnzbIV{KFOxeD2yMEBQ[3RvNDygZY5lKHOudXeg[ZhxemW\|c3nvci=>	MoD5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUe1NFgoRjJ2Mkm3OVA5RC:jPh?=
MCF7-HER2	NY\jV25NTnWwY4Tpc44hSXO\|YYm=	MnTPOUDPxE1?	M3y0cVI1KGh?	MWjEUXNQ	MUDk[YNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Yx{KG:oIFXNWEBu[XKtZYLzMEB3cW2nboTpckBidmRic3z1[y=>	M1HPfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mkm3OVA5Lz5{NEK5O\|UxQDxxYU6=
MCF7-HER2	NHfXVVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXGOUDPxE1?	NEX4SVYzPCCq	MkDtSG1UVw>?	MoTJ[Y5p[W6lZYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiClb33ibY5m\CC5aYToJGhmemOncITpci=>	M3K0UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mkm3OVA5Lz5{NEK5O\|UxQDxxYU6=
HMECs	MlrBSpVv[3Srb36gRZN{[Xl?	MmSyNVAh\|ryP	MoWyNkBp		NWHqN\|RLcW6qaXLpeJMhUU[QzsJCpI1m\GmjdHXkJJBpd3OyaH;yfYxifGmxbjDv[kBUXEGWMTygV3RCXDJiYX7kJHNVSVR\|	M33aWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkGxN\|I4Lz5{NEKxNVMzPzxxYU6=
HTR8/SVneo	NHHiZ5lHfW6ldHnvckBCe3OjeR?=	NITUUZYyyqEQvF5CpC=>	MX:xxsBp		M1Xt[pN2eHC{ZYPz[YQhV1OPLXnu[JVk\WRiU2TBWFMheGixc4Doc5J6dGG2aX;u	NXjOW29JRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOlAzPDFpPkK0NFYxOjRzPD;hQi=>
HTR8/SVneo	M17qVGZ2dmO2aX;uJGF{e2G7	NGjXOHYxNjVxMdMg{txOyqB?	MnroOFghcA>?		MULy[ZN1d3KnczD0bIUh\XiycnXzd4lwdiCxZjDFMYNi\GincnnuJJN2eHC{ZYPz[YQh[nliT2PN	Mn\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNkCyOFEoRjJ2ME[wNlQyRC:jPh?=
HTR8/SVneo	NHPtfG9HfW6ldHnvckBCe3OjeR?=	NEjRUY4yyqEQvF5CpC=>	NUnFcmVNPDhiaB?=		MYHzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCvaXfyZZRqd25iYomgU3NOyqB?	NELBVoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC2NFI1OSd-MkSwOlAzPDF:L3G+
C13*	MYnBdI9xfG:\|aYOgRZN{[Xl?	NWnmSY1SOC1zMDFOwG0>	M2jSSlI1NzR6IHi=		MULpcoR2[2W\|IHHwc5B1d3OrczDpckBiKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70JI1idm6nch?=	MmrsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7NkK1OVgoRjJ\|OU[yOVU5RC:jPh?=
OV2008	MoDRRZBweHSxc3nzJGF{e2G7	MYqwMVExKM7:TR?=	MnTWNlQwPDhiaB?=		NHXnOYdqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=>	NFjLbVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2NlU2QCd-MkO5OlI2PTh:L3G+
C13*	MXfBdI9xfG:\|aYOgRZN{[Xl?		NGnHdlkzPC92ODDo		NUOySVJM\W6qYX7j[ZMh[2m\|cHzheIlvNWmwZIXj[YQh[XCxcITvd4l{	NF;ROY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2NlU2QCd-MkO5OlI2PTh:L3G+
OV2008	NGfne25CeG:ydH;zbZMhSXO\|YYm=		MknXNlQwPDhiaB?=		NUO5PFZu\W6qYX7j[ZMh[2m\|cHzheIlvNWmwZIXj[YQh[XCxcITvd4l{	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4MkW1PEc,OjN7NkK1OVg9N2F-
W480	NFm1cGRHfW6ldHnvckBCe3OjeR?=	M{nKSVIvPS9zMDFOwG0>	MWCzNEBucW5?	NUPWT4Y4TE2VTx?=	MWXz[Y5{cXSrenXzJINmdGy\|IITvJINp\W2xcnHkbY91cGW{YYD5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl\|NEm3Nkc,OjN7M{S5O\|I9N2F-
SW837	NUX0bXJoTnWwY4Tpc44hSXO\|YYm=	MVmyMlUwOTBizszN	MXOzNEBucW5?	NHnVOZpFVVOR	Mm\Cd4Vve2m2aYrld{Bk\WyuczD0c{BkcGWvb4Lh[IlwfGincnHwfUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NVzweIttRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5N\|Q6PzJpPkKzPVM1QTd{PD;hQi=>
T24	NFLDdm5HfW6ldHnvckBCe3OjeR?=	MnL5Nk8yOC9{MDFOwG0>	MXqyOEBp		M1jHUYNifXOnczDkc5NmNWSncHXu[IVvfCCrbnjpZol1cW:wIH;mJJRp\SCFWFPMNVIucW6mdXPl[EBqdmO{ZXHz[UBw\iCrbo\h[Ilv\yClZXzsdy=>	NHLKVZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WyOlA4QSd-MkO1NlYxPzl:L3G+
CNE1	NUSzbnY4TnWwY4Tpc44hSXO\|YYm=	NHz3Um4zOCEEtV2=	NWKzVXo4PDhiaB?=		NHrBcFhjdG:la4OgeIhmKEmOLU[gbY5kemWjc3XkJJBpd3OyaH;yfYxifGmxbjDv[kBUfGG2Mx?=	NWS0N5dqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPFI6OTRpPkKzN\|gzQTF2PD;hQi=>
CNE2	MlOySpVv[3Srb36gRZN{[Xl?	NHjTT3MzOCEEtV2=	M4LSdFQ5KGh?		MWjicI9kc3NidHjlJGlNNTZiaX7jdoVie2WmIIDoc5NxcG:{eXzheIlwdiCxZjDTeIF1Ow>?	NEfaW249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O4NlkyPCd-MkOzPFI6OTR:L3G+
HONE1	M1rQWWZ2dmO2aX;uJGF{e2G7	MWOyNEDDvU1?	NXjD[W0xPDhiaB?=		MX\icI9kc3NidHjlJGlNNTZiaX7jdoVie2WmIIDoc5NxcG:{eXzheIlwdiCxZjDTeIF1Ow>?	MkLEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|OEK5NVQoRjJ\|M{iyPVE1RC:jPh?=
CNE1	Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfZUZA1KM7:TR?=			MYjzbYdvcW[rY3HueIx6KHKnZIXj[ZMh[2WubDD2bYFjcWyrdIm=	NHvVdo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O4NlkyPCd-MkOzPFI6OTR:L3G+
CNE1	M3PnemZ2dmO2aX;uJGF{e2G7	NYLrbIVHOC1{MDFOwG0>	MnPMNE01KGh?		MYTpcohq[mm2czDTeIF1OyCjY4TpeoF1cW:wIHnuJIEh\G:\|ZT2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?=	M1\2S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{iyPVE1Lz5{M{O4NlkyPDxxYU6=
CNE2	Mnr3SpVv[3Srb36gRZN{[Xl?	Mmf5NE0zOCEQvF2=	NIjvWVcxNTRiaB?=		NXq4SGR3cW6qaXLpeJMhW3SjdEOgZYN1cX[jdHnvckBqdiCjIHTvd4UuKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI>	MkLSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|OEK5NVQoRjJ\|M{iyPVE1RC:jPh?=
HONE1	MmHhSpVv[3Srb36gRZN{[Xl?	MlW2NE0zOCEQvF2=	NVraWXZ1OC12IHi=		NIHPTXBqdmirYnn0d{BUfGG2MzDhZ5RqfmG2aX;uJIlvKGFiZH;z[U0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=>	M2LUTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{iyPVE1Lz5{M{O4NlkyPDxxYU6=
CNE1	NIPMdJVE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MkC3NE42NTZ2IN88US=>	MnzFOFghcA>?		MkTDd5VxeHKnc4Pld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3WtJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK=	M1jZVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{iyPVE1Lz5{M{O4NlkyPDxxYU6=
CNE2	MULD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M3jXeFAvPS14NDFOwG0>	MmfwOFghcA>?		MkjWd5VxeHKnc4Pld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3WtJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN6MkmxOEc,OjN\|OEK5NVQ9N2F-
HONE1	NHXmXFBE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NVj0UpNxOC53LU[0JO69VQ>?	M2TQOlQ5KGh?		MULzeZBxemW\|c3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?=	MnKwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|OEK5NVQoRjJ\|M{iyPVE1RC:jPh?=
C666-1	MWHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NGjsXHoxNjVvNkSg{txO	MXO0PEBp		NWPtfYdle3WycILld5NmeyClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4UuKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI>	M3LDWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{iyPVE1Lz5{M{O4NlkyPDxxYU6=
CNE1	M130S2Fxd3C2b4Ppd{BCe3OjeR?=	MmLyNVAhyrWPwrC=	MYi0PEBp		MliybY5lfWOnczDhdI9xfG:\|aYRCpC=>	M{P6VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{iyPVE1Lz5{M{O4NlkyPDxxYU6=
CNE2	NYTFSW1PSXCxcITvd4l{KEG\|c3H5	Ml\PNVAhyrWPwrC=	NV\UN4xxPDhiaB?=		NUntZZJwcW6mdXPld{BieG:ydH;zbZPDqA>?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN6MkmxOEc,OjN\|OEK5NVQ9N2F-
HONE1	M4HH[2Fxd3C2b4Ppd{BCe3OjeR?=	M1TOOlExKML3TdMg	Mn3EOFghcA>?		NHrYXXlqdmS3Y3XzJIFxd3C2b4Ppd:Kh	M1H5c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{iyPVE1Lz5{M{O4NlkyPDxxYU6=
CNE2	NIDLfmhE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MWmxM\|Ih\|ryP	M{n6UVQ5KGh?		M1LwdJNmdnOrdHn6[UBk\WyuczD0c{Bz[WSrb4To[ZJieHl?	MoHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|OEK5NVQoRjJ\|M{iyPVE1RC:jPh?=
HONE1	NHvaR21E\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MXmxM\|Ih\|ryP	M2XVWlQ5KGh?		MXrz[Y5{cXSrenWgZ4VtdHNidH:gdoFlcW:2aHXyZZB6	M2rzUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{iyPVE1Lz5{M{O4NlkyPDxxYU6=
C666-1	MVHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NWfnfGJlOS9{IN88US=>	NIXYRVU1QCCq		NVHKc4dIe2Wwc3n0bZpmKGOnbHzzJJRwKHKjZHnveIhmemGyeR?=	NWLWVVZxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPFI6OTRpPkKzN\|gzQTF2PD;hQi=>
HEC-1A	MUnGeY5kfGmxbjDBd5NigQ>?	NUnKOJdvOcLizszNxsA>	MoTGNlQhcA>?	NYLZeFdZTE2VTx?=	MUTicI9kc3NidHjlJG1WSzJyLXXubIFv[2WmIHnueoF{cW:wIITybYdo\XKnZDDifUAyOCViRlLT	M{fH[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|Mk[yNlA5Lz5{M{K2NlIxQDxxYU6=
RL95-2	NGfkU2dHfW6ldHnvckBCe3OjeR?=	MnfuNeKh\|ryPwrC=	Mn;tNlQhcA>?	NGH2cIxFVVOR	MlvkZoxw[2u\|IITo[UBOXUN{MD3lcohidmOnZDDpcpZie2mxbjD0dolo\2W{ZXSgZpkhOTBnIF\CVy=>	MkTiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NkKyNFgoRjJ\|Mk[yNlA5RC:jPh?=
HEC-1A	NXnYOYM1TnWwY4Tpc44hSXO\|YYm=	NGXy[XQyyqEQvF5CpC=>	NWS5U\|FFOjRiaB?=	M2HFT2ROW09?	MlnSZoxw[2u\|IITo[UBOXUN{MD3lcohidmOnZDDpcpZie2mxbjD0dolo\2W{ZXSgZpkhTUeIwrC=	MoC0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NkKyNFgoRjJ\|Mk[yNlA5RC:jPh?=
RL95-2	M2nKfGZ2dmO2aX;uJGF{e2G7	MU[xxsDPxE4EoB?=	M4LCc\|I1KGh?	NE\6cJFFVVOR	NUf0VWQ3[myxY3vzJJRp\SCPVVOyNE1mdmijbnPl[EBqdn[jc3nvckB1emmpZ3Xy[YQh[nliRVfGxsA>	MmHwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NkKyNFgoRjJ\|Mk[yNlA5RC:jPh?=
CT26	NIDSWG9HfW6ldHnvckBCe3OjeR?=	NXfrcZhtOjBibV2=	NFvU[mQyKGh?		M4PlVZN2eHC{ZYPz[ZMhUEeILXnu[JVk\WRiVlXHSkBmgHC{ZYPzbY9vyqB?	Ml[4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{M{OxOlMoRjJ\|MkOzNVY{RC:jPh?=
UM-SCC-17B	NVXtU4wyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnvjTWM2OD1{LkW2NkDDuSByLkSwPUDPxE1uIFfJOVA:OS5{N{mgxtEhOC5zOUSg{txO	M2jwWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{ewPFk6Lz5{Mke3NFg6QTxxYU6=
OSC-19	NFHaNllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXi2PVJnUUN3ME2zMlQ5OSEEsTCwMlk2OyEQvF2sJGdKPTB;MT6zOlYhyrFiMD63O\|Ah\|ryP	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd5MEi5PUc,OjJ5N{C4PVk9N2F-
Cal33	M4TBVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoDvTWM2OD1{LkK4NkDDuSByLkSyN{DPxE1uIFfJOVA:OS5\|NEmgxtEhOC5\|NkOg{txO	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd5MEi5PUc,OjJ5N{C4PVk9N2F-
UM-SCC-22B	M13uS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXvWmpwUUN3ME2yMlY1QCEEsTCwMlU1OiEQvF2sJGdKPTB;MT6zNlAhyrFiMD6yNFQh\|ryP	NIXwO5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke3NFg6QSd-MkK3O\|A5QTl:L3G+
UM-SCC-17B	NIrQdVdHfW6ldHnvckBCe3OjeR?=	MUSwMVMxKM7:TR?=	Mn[2NE0zPCCq		NHnFRYJqdmirYnn0d{BUXEGWMzDhZ5RqfmG2aX;uJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm=	NFjQTHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke3NFg6QSd-MkK3O\|A5QTl:L3G+
OSC-19	M4foW2Z2dmO2aX;uJGF{e2G7	MkDWNE0{OCEQvF2=	M3fK[VAuOjRiaB?=		MkH0bY5pcWKrdIOgV3RCXDNiYXP0bZZifGmxbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7	MlmwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5N{C4PVkoRjJ{N{ewPFk6RC:jPh?=
Cal33	M1vXe2Z2dmO2aX;uJGF{e2G7	M{PueFAuOzBizszN	M{PzdlAuOjRiaB?=		MmjybY5pcWKrdIOgV3RCXDNiYXP0bZZifGmxbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7	M{HOVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{ewPFk6Lz5{Mke3NFg6QTxxYU6=
UM-SCC-22B	MnHYSpVv[3Srb36gRZN{[Xl?	NV6zWVJUOC1\|MDFOwG0>	NETWRZoxNTJ2IHi=		NWT6[HlqcW6qaXLpeJMhW1SDVEOgZYN1cX[jdHnvckBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5	M{e5OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{ewPFk6Lz5{Mke3NFg6QTxxYU6=
U-87MG	Mkj1R4VtdCCYaXHibYxqfHliQYPzZZk>	MYSwMVExKM7:TR?=	MVu3NkBp	NE\xR4xFVVOR	NY\HcXpocW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR\|Nk[4Nkc,OjV2M{[2PFI9N2F-
U-373MG	MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MoHTNE0yOCEQvF2=	MnO2O\|IhcA>?	MU\EUXNQ	NVXtUG1pcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR\|Nk[4Nkc,OjV2M{[2PFI9N2F-
SH-SY5Y	MVTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NHL3WZkxNTFyIN88US=>	MmfWO\|IhcA>?	MnTzSG1UVw>?	NGnqS5BqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	NFm0blk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSzOlY5Oid-MkW0N\|Y3QDJ:L3G+
Tu-9648	M{TlbmNmdGxiVnnhZoltcXS7IFHzd4F6	NWjm[lVvOC1zMDFOwG0>	NIPsXGs4OiCq	MkT2SG1UVw>?	NULvS\|NEcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	MmDGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2M{[2PFIoRjJ3NEO2OlgzRC:jPh?=
Neuro-2a	M4ryTmNmdGxiVnnhZoltcXS7IFHzd4F6	NEXOPFIxNTFyIN88US=>	MWS3NkBp	MmLDSG1UVw>?	NWSyV4RicW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	M1S3[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEO2OlgzLz5{NUSzOlY5OjxxYU6=
PCNs	MmXyR4VtdCCYaXHibYxqfHliQYPzZZk>	NV;MVYdGOC1zMDFOwG0>	MWS3NkBp	M4fUNmROW09?	M{\HUYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	M{m5dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEO2OlgzLz5{NUSzOlY5OjxxYU6=
PGCs	Ml7OR4VtdCCYaXHibYxqfHliQYPzZZk>	M1:wNVAuOTBizszN	MlPzO\|IhcA>?	MX3EUXNQ	MmrXbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	NHTONnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSzOlY5Oid-MkW0N\|Y3QDJ:L3G+
RAW264.7	NGPGSG1HfW6ldHnvckBCe3OjeR?=	M1jVSFExKM7:TR?=	M4jn[lEzKGh?		NHL0cWFi[nKxZ3H0[ZMhfGinIH3SUmEh\XiycnXzd4lwdnNib3[gTmFMOixiU2TBWFEtKFOWQWSyMEBidmRiU2TBWFMhcW6mdXPl[EBjgSCGT16gZY5lKFRvMjD0c5hqdg>?	NF;EdGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS1OFQ{OSd-MkK0OVQ1OzF:L3G+
RAW264.7	NH\pWZJCeG:ydH;zbZMhSXO\|YYm=	M13jd\|UwOTBizszN	NWfqUmZJPDVibXnu		Mlvk[Y5p[W6lZYOgeI95cW6\|IHnu[JVk\WRiYYDvdJRwe2m\|IHHu[EBOVVBibH;zdy=>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR3NESzNUc,OjJ2NUS0N\|E9N2F-
SW480	MnSzR4VtdCCYaXHibYxqfHliQYPzZZk>	Mm\XOU8yOC9{MDFOwG0>	MYS3NkBp		MV7pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCxZjD0bIUhSUyGSDuvR2QyOzNtwrDj[Yxtew>?	NWT2Vm5oRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5NFA{QTdpPkKxPVAxOzl5PD;hQi=>
HCT116	MVnD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MlnsOU8yOC9{MDFOwG0>	NXTzfpN5PzJiaB?=		MWXpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCxZjD0bIUhSUyGSDuvR2QyOzNtwrDj[Yxtew>?	Mk\FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7MECzPVcoRjJzOUCwN\|k4RC:jPh?=
DLD-1	NInZUZBE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M4jhdlUwOTBxMkCg{txO	NVu4ZXo4PzJiaB?=		M4nRc4lvcGmkaYTzJINmdGxidnnhZoltcXS7IH;mJJRp\SCDTFTIL{9ETDF\|MzxCpINmdGy\|	NW\XXJJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5NFA{QTdpPkKxPVAxOzl5PD;hQi=>
SNU387	Mn\YR4VtdCCYaXHibYxqfHliQYPzZZk>	M4fn[FIxyqEQvF5CpC=>	NW\qW4d2OjRiaB?=		NWfyOZBoemWmdXPld{Bk\WyuII\pZYJqdGm2eR?=	NGXSO5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUOxNVk4PSd-MkGzNVE6PzV:L3G+
SNU398	NHe0S4FE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M2O3e\|IxyqEQvF5CpC=>	NE\JPXQzPCCq		MVTy[YR2[2W\|IHPlcIwhfmmjYnnsbZR6	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTNzMUm3OUc,OjF\|MUG5O\|U9N2F-
HepG2	MmD2R4VtdCCYaXHibYxqfHliQYPzZZk>	Mly2NlDDqM7:TdMg	NV3zOmtCOjRiaB?=		NF3QNGFz\WS3Y3XzJINmdGxidnnhZoltcXS7	M174T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{GxPVc2Lz5{MUOxNVk4PTxxYU6=
Huh-7	Mk\GR4VtdCCYaXHibYxqfHliQYPzZZk>	MnPCNlDDqM7:TdMg	MWmyOEBp		M1TMbpJm\HWlZYOgZ4VtdCC4aXHibYxqfHl?	MmTQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF\|MUG5O\|UoRjJzM{GxPVc2RC:jPh?=
VSMC	NE\I[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVqzM\|UwOTBizszN	MWCzNEBucW5?	NFu4T5pFVVOR	M{\VepBz\X[nboTzJHBFT0ZvIHHu[EB1cHKxbXLpck1u\WSrYYTl[EBXW02FIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NF;nNZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi0O\|MxPid-MkC4OFc{ODZ:L3G+
MDA-MB-231	MULBdI9xfG:\|aYOgRZN{[Xl?	MVSxNEDPxE1?	NFy2O3EzPCCq	MUPEUXNQyqB?	M13Gb4lv\HWlZYOgZZBweHSxc3nz	NGC3c3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{GxOFAxPSd-MUexNVQxODV:L3G+
MDA-MB-435S	MUfBdI9xfG:\|aYOgRZN{[Xl?	MmDDNVAh\|ryP	NH;ISIEzPCCq	MoXvSG1UV8Li	Mom0bY5lfWOnczDhdI9xfG:\|aYO=	M{HCdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUG0NFA2Lz5zN{GxOFAxPTxxYU6=
AsPC1	NHe1fJNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M1\wTlczKGi{cx?=		MmfKRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDc2DDNUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDJR\|UxKD1iMT6zNkDPxE1w	NV\YZmVGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFQ6PjZpPkK0PVA1QTZ4PD;hQi=>
MDA-MB-231	MXrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NF3aSYE4OiCqcoO=		NYDGfZd7SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBGWi2wZXfheIl3\SCjbnSgeJJqeGynLX7l[4F1cX[nIHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFIvQDlizszNMi=>	NV3kc41SRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFQ6PjZpPkK0PVA1QTZ4PD;hQi=>
MCF7	NUDJZ2tNSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Mn70O\|IhcHK\|		NWDCdZV{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBGWi2yb4PpeIl3\SCqdX3hckBOS0Z5IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGGodHXyJFczKGi{czDifUBOXFNiYYPzZZktKEmFNUCgQUA{NjZizszNMi=>	MnLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MES5OlYoRjJ2OUC0PVY3RC:jPh?=
PANC1	NVrEPY5WSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MnznO\|IhcHK\|		NIjaUVJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDBUmMyKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO\|YYmsJGlEPTBiPTCzMlc4KM7:TT6=	MoPZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MES5OlYoRjJ2OUC0PVY3RC:jPh?=
MDA-MB-231	NXn4fZI2S3m2b4TvfIlkcXS7IHHzd4F6		M{LBOlQ5KGi{cx?=		MVfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxMlU3KM7:TT6=	M{CwXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{m2Olg6Lz5{NkO5OlY5QTxxYU6=
MDA-MB-435S	MYfDfZRwfG:6aXPpeJkh[XO\|YYm=		NVLUR5dWPDhiaILz		MnO2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUSzOXMh[2WubIOgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFEvQDdizszNMi=>	NX2yT4Q1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVY3QDlpPkK2N\|k3Pjh7PD;hQi=>
MCF7	MlTqR5l1d3SxeHnjbZR6KGG\|c3H5		MofSOFghcHK\|		NXHlNJpvS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMj6xOkDPxE1w	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN7Nk[4PUc,OjZ\|OU[2PFk9N2F-
A549	MX\DfZRwfG:6aXPpeJkh[XO\|YYm=		NEX4UGE1QCCqcoO=		M3PzeWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDJwNTFOwG0v	Ml2zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|OU[2PFkoRjJ4M{m2Olg6RC:jPh?=
DU145	NITNXnNEgXSxdH;4bYNqfHliYYPzZZk>		NYjEe2N[PDhiaILz		NXHEXVBDS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEKuOUDPxE1w	NVrYWXZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVY3QDlpPkK2N\|k3Pjh7PD;hQi=>
PANC1	M2PsT2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NX3vN3d[PDhiaILz		Mnv0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGFPSzFiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDJwOTFOwG0v	NFG0S\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5OlY5QSd-Mk[zPVY3QDl:L3G+
HCT116	NW\kUGxKSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NXTx[plrPzJiaILz		NHzQTYFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNU4xQCEQvF2u	NUHoVoxJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3NVg1PzBpPkK3O\|E5PDdyPD;hQi=>
MDA-MB-231	Mnu1RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MUi3NkBpenN?		MmK4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAyNjZ6IN88UU4>	NEP5Vmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{exPFQ4OCd-Mke3NVg1PzB:L3G+
MCF7	M1\jfGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M2\Ud\|czKGi{cx?=		NF7hUodCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEKuN\|Yh\|ryPLh?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzdzOES3NEc,Ojd5MUi0O\|A9N2F-
A549	NWfJb\|dpSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MXG3NkBpenN?		MYHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDRwNDFOwG0v	M3XURlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{G4OFcxLz5{N{exPFQ4ODxxYU6=
AD293	MmTuSpVv[3Srb36gZZN{[Xl?		Mny1OkBpenN?		NGrpTZRKdmirYnn0bY9vKG:oIFnGUodidW2jLYP0bY12dGG2ZXSgS2ZRN0[OQVeteIFo\2WmIGPURXQ{KGSrbXXybZpifGmxbjDpckBpfW2jbjDBSFI6OyClZXzsd{BqdmO3YnH0[YQh\m:{IE[gbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpd{whUUN3MDC9JFUvOSEQvF2u	NX;UOWhuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyNlgxODBpPkOwNlI5ODByPD;hQi=>
MDA-MB-231	M4DX[GZ2dmO2aX;uJIF{e2G7	NETTcIQyKHSxIEGwJJVO	MnHsNVIhcHK\|		NH7xcWJKdmirYnn0bY9vKG:oIGPURXQ{KHCqb4PwbI9zgWyjdHnvckBifCCWeYK3NFUhcW5iaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BifCBzIITvJFExKHWPIHHmeIVzKDF{IHjyd{BjgSC5ZYP0[ZJvKGKub4SgZY5idHm\|aYO=	M4LPeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUC0PVY3Lz5{NEmwOFk3PjxxYU6=
MDA-MB-231	M1XHT2FvfGmlYX7j[ZIh[XO\|YYm=	MVqxJJRwKDFyIIXN	NXv0SWNbPDhiaILz		MmnYRY51cWOjbnPldkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdixiYYDvdJRwe2m\|IHHu[EBk\WyudXzhdkBud3KyaH;sc4dq[2GuIHPoZY5o\XNiYYSgNUB1dyBzMDD1UUBi\nSncjC0PEBpenNiYomgcIlocHRibXnjdo9{[2:yeR?=	NGfWRXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwOFk3Pid-MkS5NFQ6PjZ:L3G+
MDA-MB-231	M2nYS2Z2dmO2aX;uJIF{e2G7	M3fkW\|EhfG9iMUCgeW0>	Ml3JNVIhcHK\|		NVXtSFk{TGWlcnXhd4UhcW5iU2TBWFMheHKxdHXpckBmgHC{ZYPzbY9vKGmwIHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XRiMTD0c{AyOCC3TTDh[pRmeiBzMjDodpMh[nlid3XzeIVzdiCkbH;0JIFv[Wy7c3nz	NGe0PVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwOFk3Pid-MkS5NFQ6PjZ:L3G+
MCF7	MY\GeY5kfGmxbjDhd5NigQ>?		MmPDNVIhcHK\|		MluyTY5pcWKrdHnvckBw\iCVVFHUN{BxcG:\|cHjvdplt[XSrb36gZZQhYTdyNTDpckBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEGyJIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	NUTzNFJJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVY3QDlpPkK2N\|k3Pjh7PD;hQi=>
MDA-MB-435S	NF;iSolHfW6ldHnvckBie3OjeR?=		NYn3TJRnOTJiaILz		MXjJcohq[mm2aX;uJI9nKFOWQWSzJJBpd3OyaH;yfYxifGmxbjDheEB[PzB3IHnuJIh2dWGwIF3ERU1OSi12M{XTJINmdGy\|IHHmeIVzKDF{IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	NFn6cXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5OlY5QSd-Mk[zPVY3QDl:L3G+
MDA-MB-231	Ml7NSpVv[3Srb36gZZN{[Xl?		NUnLdmsyOTJiaILz		NVjBOYZkUW6qaXLpeIlwdiCxZjDTWGFVOyCyaH;zdIhwenmuYYTpc44h[XRiWUewOUBqdiCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIFnfGW{IEGyJIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	MkHtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|OU[2PFkoRjJ4M{m2Olg6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-STAT3 / STAT3 ; PubMed: 25261365 Oncotarget (A) PC3M-1E8 cells were treated with different doses of Stattic for 4 h. (B) PC3M-1E8 cells were treated with 10 μM Stattic for different time points. Survivin / c-Myc / Bcl-xl ; PubMed: 25261365 Oncotarget Western blot analysis of STAT3 downstream targets in PC3M-1E8 cells treated with 10 μM Stattic for 24 h. PARP / C-PARP / Caspase-3 / C-Caspse-3 ; PubMed: 23382914 PLoS One NPC cells were exposed to the indicated concentrations of Stattic for 48 h; apoptotic cells were measured by western blot analysis of cleaved PARP and cleaved caspase-3. Protein levels were quantified using ImageJ software.	25261365 23382914
Immunofluorescence	p-STAT3 / STAT3 / Survivin ; PubMed: 25261365 Oncotarget Cellular localization of pSTAT3 and survivin (green) was observed by confocal microscopy after immunofluorescent staining of PC3M-1E8 cancer cells treated with 10 μM Stattic.	25261365
Growth inhibition assay	Cell viability; PubMed: 23382914 PLoS One Stattic inhibits the cell viability of NPC cells in a time-dependent manner. CNE2 cells were treated with 8 µM Stattic for the indicated times, and cell viability was measured by the MTT assay.	23382914
ELISA	BDNF; PubMed: 27456333 Sci Rep BDNF secretion was analyzed using ELISA in A549 and H1299 cells treated with or without Stattic. Results are shown as the mean ± S.E. n = 3; *p < 0.05, vs Control group, Student’s t-test.	27456333

激酶实验： ^[1]	- 合并高通量筛选和荧光偏振检测: 在约30°C下进行筛选。通过实验化合物与STAT1, STAT5, 和 Lck 的SH2结构域结合的类似实验验证筛选的特异性。所有FP实验的Buffer组分的终浓度为10 mM HEPES(pH 7.5),1 mM EDTA,0.1% Nonidet P-40,50 mM NaCl,和10% DMSO。二硫苏糖醇的存在对抑制活性是必不可少的。肽序列为:STAT3,5-carboxyfluorescein-GY(PO₃H₂)LPQTV-NH2; STAT1, 5-carboxyfluorescein-GY(PO₃H₂)DKPHVL;STAT5, 5-carboxyfluorescein-GY(PO₃H₂)LVLDKW; 和 Lck, 5-carboxyfluorescein-GY(PO₃H₂)EEIP。在 30°C下进行特异性分析, 使用150 nM蛋白(STAT1,STAT3,和STAT5)。在37°C下进行分析，使用370 nM 蛋白(STAT3)或100 nM蛋白 (Lck)。蛋白与实验化合物在Eppendorf管中在指定温度环境下温育60分钟，然后加入相应的5-carboxyfluorescein标记的肽（终浓度为10 nM）。混合物至少平衡30分钟，然后在室温下测量。实验化合物在20×stock在DMSO中稀释到指定浓度。使用 SigmaPlot绘制结合曲线和抑制曲线。独立实验中，所有竞争曲线都需重复三次。
细胞实验： ^[2]	- 合并 Cell lines: Ly3细胞 Concentrations: ~2.5 μM Incubation Time: 48小时 Method: MTS (Only for Reference)
动物实验： ^[2]	- 合并 Animal Models: Ly3亲本NOD/SCID IL2R移植瘤 Dosages: 每天3.75 mg/kg Administration: 瘤内注射 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	42 mg/mL (198.87 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O	10mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Stattic SDF

分子量	211.19
化学式	C₈H₅NO₄S
CAS号	19983-44-9
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
We need to dissolve the compound for i.p. injection, could you give me some suggestions?
回答：
S7024 Stattic can be dissolved in 2% DMSO/PEG 300/dd H2O at 8 mg/mL as a clear solution.

研究领域

产品类型

定制您的化合物库

Stattic

客户使用Selleck生产的Stattic发表文献139篇：

产品安全说明书

STAT抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Stattic SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

常见问题及建议解决方法

STAT Signaling Pathway Map

相关STAT产品